Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Entero Therapeutics, Inc. (ENTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ENTO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -57.2% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.11M USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 397338 | Beta 1.37 | 52 Weeks Range 0.18 - 4.11 | Updated Date 04/2/2025 |
52 Weeks Range 0.18 - 4.11 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Earnings Date
Report Date 2025-03-27 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.07% | Return on Equity (TTM) -15.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66339096 | Price to Sales(TTM) - |
Enterprise Value 66339096 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 3253290 | Shares Floating 2421702 |
Shares Outstanding 3253290 | Shares Floating 2421702 | ||
Percent Insiders 7.22 | Percent Institutions 5.98 |
Analyst Ratings
Rating 4 | Target Price 36 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Entero Therapeutics, Inc.
Company Overview
History and Background
There is currently no publicly traded company under the name 'Entero Therapeutics, Inc.' in the US stock market. Therefore, I can't provide a history or background.
Core Business Areas
Leadership and Structure
Given the absence of a publicly traded entity named 'Entero Therapeutics, Inc.', I cannot describe its leadership or organizational structure.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Due to the lack of information on a publicly traded 'Entero Therapeutics, Inc.', an industry overview cannot be provided.
Positioning
Without information on Entero Therapeutics, Inc., I cannot describe its positioning.
Total Addressable Market (TAM)
Since no company information is available, I can't provide this information.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Competitive landscape information cannot be provided without company information.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth information cannot be provided without company information.
Future Projections: Future projections cannot be provided without company information.
Recent Initiatives: Recent initiatives cannot be provided without company information.
Summary
Based on the inability to find a publicly traded US stock under the name 'Entero Therapeutics, Inc.', it's impossible to provide any meaningful analysis. There is no data to assess its strengths, weaknesses, opportunities, or threats, nor its overall financial health or competitive positioning.
Similar Companies
Sources and Disclaimers
Data Sources:
- Publicly available SEC filings, financial news sources. (None Found)
- Google Search (No relevant publicly traded company found)
Disclaimers:
The information provided is based on the absence of a publicly traded company under the name 'Entero Therapeutics, Inc.' in the US stock market. Any resemblance to an actual company is purely coincidental. This analysis should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entero Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-10-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.enterothera.com |
Full time employees 9 | Website https://www.enterothera.com | ||
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.